AI-designed dog vaccine shrinks tumor 75%, boosting Moderna oncology platform
A Sydney entrepreneur used ChatGPT and UNSW’s RNA platform to design a personalized mRNA vaccine that shrank his dog’s tumor by 75% in two months after sequencing $3,000 of DNA. The milestone validates Moderna’s personalized oncology platform, whose melanoma vaccine cut recurrence risk by 49% over five years.
1. AI-Designed Canine mRNA Vaccine
Tech entrepreneur Paul Conyngham sequenced $3,000 of his dog Rosie’s healthy and tumor DNA at UNSW, then used ChatGPT and AlphaFold to design a bespoke mRNA vaccine that reduced a tennis ball–sized mast cell tumor by 75% within two months of the first injection.
2. Validation of Personalized Oncology Platform
This case demonstrates the accessibility and rapid development potential of mRNA platforms, reinforcing investor confidence in Moderna’s pipeline pivot toward personalized oncology beyond its COVID-19 franchise.
3. Human Trial Success in Melanoma
Moderna and Merck’s intismeran autogene showed a consistent 49% reduction in melanoma recurrence or death over five years in combined trials with Keytruda, and Phase 3 studies in melanoma and non–small-cell lung cancer are currently underway.
4. Market Potential and Financial Outlook
The broader mRNA therapeutics market was valued at $7.7 billion in 2025, with personalized cancer vaccines expected to price near $200,000 per patient and achieve multibillion-dollar peak sales; Moderna generated $1.9 billion in revenue in 2025, down 40% year-over-year.